Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?

This publication has 16 references indexed in Scilit:

• Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?
  New England Journal of Medicine, 1992
• A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
  Circulation, 1991
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
  The American Journal of Cardiology, 1990
• A Comparison between Heparin and Low-Dose Aspirin as Adjunctive Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction
  New England Journal of Medicine, 1990
• The antiplatelet effect of daily low dose enteric-coated aspirin in man: A time course of onset and recovery
  Thrombosis Research, 1990
• Guidelines for the early management of patients with acute myocardial infarction
  Journal of the American College of Cardiology, 1990
• A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.
  Circulation, 1989
• Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
  Blood, 1987
• Cumulative antiplatelet effect of low‐dose enteric coated aspirin
  British Journal of Haematology, 1985
• Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
  Journal of Clinical Investigation, 1982